{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:55:42Z","timestamp":1761872142605,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clml.2022.04.019","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T02:46:26Z","timestamp":1650595586000},"page":"680-689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Jonathan","family":"Avery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namrata","family":"Chandhok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanelle","family":"Rainey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Huntington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Isufi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Seropian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina L","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7843-3162","authenticated-orcid":false,"given":"Francine","family":"Foss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.04.019_bib0001","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ajh.24791","article-title":"The aggressive peripheral T-cell lymphomas: 2017","volume":"92","author":"Armitage","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.04.019_bib0002","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.019_bib0003","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.04.019_bib0004","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.019_bib0005","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.22715","article-title":"Leukemic involvement is a common feature in mantle cell lymphoma","volume":"109","author":"Ferrer","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.04.019_bib0006","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bjh.12675","article-title":"Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis","volume":"164","author":"Sarkozy","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.04.019_bib0007","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/jclinpath-2013-201748","article-title":"Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis","volume":"67","author":"Horna","year":"2014","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.clml.2022.04.019_bib0008","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2018.01.076","article-title":"Blood classification and blood response criteria in mycosis fungoides and Sezary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force","volume":"93","author":"Scarisbrick","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2022.04.019_bib0009","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bjd.19669","article-title":"The importance of assessing blood tumour burden in cutaneous T-cell lymphoma","author":"Vermeer","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2022.04.019_bib0010","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.cll.2017.07.012","article-title":"Cost-effective flow cytometry testing strategies","volume":"37","author":"Leith","year":"2017","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.clml.2022.04.019_bib0011","first-page":"5.1.1","article-title":"Flow cytometry: an overview","volume":"120","author":"McKinnon","year":"2018","journal-title":"Curr Protoc Immunol"},{"key":"10.1016\/j.clml.2022.04.019_bib0012","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaad.2015.12.018","article-title":"Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vbeta chain restriction","volume":"74","author":"Gibson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2022.04.019_bib0013","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000500666","article-title":"Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE registry","volume":"143","author":"Lansigan","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2022.04.019_bib0014","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.019_bib0015","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.3109\/10428194.2016.1170827","article-title":"Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology","volume":"57","author":"Loghavi","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.04.019_bib0016","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/hon.2080","article-title":"Peripheral blood sCD3(-) CD4(+) T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma","volume":"32","author":"Singh","year":"2014","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2022.04.019_bib0017","doi-asserted-by":"crossref","first-page":"E361","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets","volume":"100","author":"de Leval","year":"2015","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:03Z","timestamp":1761871263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022001343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2152265022001343"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.019","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}